Studies on radiosensitivity from an epidemiological point of view - Overview of methods and results

Radiotherapy and Oncology

Volumn 62, Issue 3, 2002, Pages 249-260

  Twardella, Dorothee ^a   Chang Claude, Jenny ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Breast cancer; Epidemiology; Radiosensitivity; Radiotherapy; Side effects

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; ASSAY; BREAST CARCINOMA; CANCER RADIOTHERAPY; ERYTHEMA; HUMAN; PRIORITY JOURNAL; RADIATION EXPOSURE; RADIATION INJURY; RADIOSENSITIVITY; SKIN EDEMA; SKIN FIBROSIS; STATISTICAL ANALYSIS; TELANGIECTASIA;

BREAST NEOPLASMS; CELL SURVIVAL; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, RADIATION; EPIDEMIOLOGIC RESEARCH DESIGN; FEMALE; HUMANS; RADIATION TOLERANCE; RESEARCH DESIGN; SKIN;

EID: 0036227388     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-8140(01)00491-1     Document Type: Article

References (74)

1. Analysis by alkaline comet assay of cancer patients with severe reactions to radiotherapy: Defective rejoining of radioinduced DNA strand breaks in lymphocytes of breast cancer patients
2. Absence of mutations in the ATM gene in breast cancer patients with severe responses to radiotherapy
3. Molecular genotyping shows that ataxia-telangiectasia heterozygotes are predisposed to breast cancer
4. Absence of mutations in the ATM gene in forty-seven cases of sporadic breast cancer
5. Lack of correlation of human fibroblast radiosensitivity in vitro with early skin reactions in patients undergoing radiotherapy
6. Relationship between early and late normal-tissue injury after postmastectomy radiotherapy
7. Patient-to-patient variability in the expression of radiation-induced normal tissue injury
8. Clinical normal-tissue radiobiology
9. Early and late normal-tissue injury after postmastectomy radiotherapy alone or combined with chemotherapy
10. Latent-time estimation for late cutaneous and subcutaneous radiation reactions in a single-follow-up clinical study
11. Clinical correlations between late normal tissue endpoints after radiotherapy: Implications for predictive assays of radiosensitivity
12. Dose and volume effects on fibrosis after breast conservation therapy
13. Fibroblast radiosensitivity versus acute and late normal skin responses in patients treated for breast cancer
14. Prediction of normal-tissue tolerance to radiotherapy from in-vitro cellular radiation sensitivity
15. The relationship between cellular radiation sensitivity and tissue response may provide the basis for individualising radiotherapy schedules
16. Normal tissue radiosensitivity - How important is it?
17. Radiation sensitivity - From laboratory to clinic
18. Altered apoptotic profiles in irradiated patients with increased toxicity
19. Radiosensitivity in ataxia-telangiectasia
20. Response of dermal fibroblast cultures from patients with unusually severe responses to radiotherapy and from ataxia telangiectasia heterozygotes to fractionated radiation
21. Relationship between DNA double-strand breaks, cell killing, and fibrosis studied in confluent skin fibroblasts derived from breast cancer patients
22. Radiobiological models of normal tissue reactions
23. ATM heterozygosity and breast cancer: Screening of 37 breast cancer patients for ATM mutations using a non-isotopic RNase cleavage-based assay
24. Kann man extrem erhöhte strahlensensitivität von patienten durch in-vitro testung von lymphozyten erkennen?
25. Chromosomal in-vitro radiosensitivity of lymphocytes in radiotherapy patients and AT-homozygotes
26. Cancer risk in A-T heterozygotes
27. Heterozygous ATM mutations do not contribute to early onset of breast cancer
28. Prospective comparison of in vitro normal cell radiosensitivity and normal tissue reactions in radiotherapy patients
29. Ataxia telangiectasia. Neoplasia, untoward response to X-irradiation, and tuberous sclerosis
30. Evidence for a positive correlation between in vitro radiosensitivity of normal human skin fibroblasts and the occurrence of subcutaneous fibrosis after radiotherapy
31. Relationship between the in vitro radiosensitivity of skin fibroblasts and the expression of subcutaneous fibrosis, telangiectasia, and skin erythema after radiotherapy
32. Abnormal radiosensitivity of lymphocytes from breast cancer patients with excessive normal tissue damage after radiotherapy: Chromosome aberrations after low dose-rate irradiation
33. Early reactions as dose-limiting factors in radiotherapy
34. Lack of correlation between residual radiation-induced DNA damage, in Keranocytes assayed directly from skin, and late radiotherapy reactions in breast cancer patients
35. A correlation between residual radiation-induced double-strand breaks in cultured fibroblasts and late radiotherapy reactions in breast cancer patients
36. TGF-beta1 levels in pre-treatment plasma identify breast cancer patients at risk of developing post-radiotherapy fibrosis
37. In vitro radiosensitivity of human diploid fibroblasts derived from women with unusually sensitive clinical responses to definitive radiation therapy for breast cancer
38. The modelled benefits of individualizing radiotherapy patients' dose using cellular radiosensitivity assays with inherent variability
39. Radiation reaction in ataxia telangiectasia
40. Radiation-induced micronucleus formation in human skin fibroblasts of patients showing severe and normal tissue damage after radiotherapy
41. The importance of genetics for the optimization of radiation therapy. A hypothesis
42. Radiation sensitive breast cancer patients
43. Radiation-induced comet-formation in human skin fibroblasts from radiotherapy patients with different normal tissue reactions
44. EORTC late effects working group: Late effects toxicity scoring: The SOMA scale
45. No predictive value of the micronucleus assay for patients with severe acute reaction of normal tissue after radiotherapy
46. Normal tissue radiosensitivity in breast cancer patients
47. Testing for mutations of the ataxia telangiectasia gene in radiosensitive breast cancer patients
48. Four radiation hypersensitivity cases and their implications for clinical radiotherapy
49. Introduction: Late effects consensus conference: RTOG/EORTC
50. RTOG late effects working group: Overview of late effects normal tissues (LENT) scoring system
51. Low predictive value of intrinsic fibroblast radiosensitivity for fibrosis development following radiotherapy for breast cancer
52. Chromosomal radiosensitivity, cancer predisposition and response to radiotherapy
53. Radiation-induced micronucleus induction in lymphocytes identifies a high frequency of radiosensitive cases among breast cancer patients: A test for predisposition?
54. Leitlinien zur dokumentation von nebenwirkungen in der radioonkologie
55. Prevalence of germline truncating mutations in ATM in women with a second breast cancer after radiation therapy for a contralateral tumor
56. Heterozygosity for mutations in the ataxia telangiectasia gene is not a major cause of radiotherapy complications in breast cancer patients
57. Biologische grundlagen der strahlentherapie
58. The incidence and gene frequency of ataxia-telangiectasia in the United States
59. Incidence of cancer in 161 families affected by ataxia-telangiectasia
60. Radiation effects in skin
61. Evidence for individual differences in the radiosensitivity of human skin
62. How much could the radiotherapy dose be altered for individual patients based on a predictive assay of normal-tissue radiosensitivity?
63. Prognostic factors for acute and late skin reactions in radiotherapy patients
64. Radiosensitivity of normal tissues in ataxia-telangiectasia heterozygotes
65. A comparison of the radiosensitivity of lymphocytes from normal donors, cancer patients, individuals with ataxia-telangiectasia (A-T) and A-T heterozygotes
66. Variability of individual normal tissue radiation sensitivity